|
Delayed
OTC Markets
15:16:07 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 0.5055 USD | +4.06% |
|
+2.54% | -36.43% |
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Revenues | - | 113K | 89.27K | 456K | 432K | ||
Total Revenues | - | 113K | 89.27K | 456K | 432K | ||
Gross Profit | - | 113K | 89.27K | 456K | 432K | ||
Selling General & Admin Expenses, Total | 3.84M | 5.67M | 4.02M | 3.33M | 4.88M | ||
Stock-Based Compensation (IS) | 1.21M | 1.25M | 1.43M | 596K | 820K | ||
R&D Expenses | - | - | - | - | - | ||
Depreciation & Amortization - (IS) | - | 597K | 610K | - | - | ||
Other Operating Expenses, Total | 5.05M | 7.51M | 6.06M | 3.93M | 5.7M | ||
Operating Income | -5.05M | -7.4M | -5.97M | -3.47M | -5.26M | ||
Currency Exchange Gains (Loss) | - | - | - | - | - | ||
Other Non Operating Income (Expenses) | -37.95K | - | 110K | 140K | 41.7K | ||
EBT, Excl. Unusual Items | -5.08M | -7.4M | -5.86M | -3.33M | -5.22M | ||
Merger & Related Restructuring Charges | - | -534K | - | - | - | ||
Impairment of Goodwill | - | -4.03M | -6.41M | - | - | ||
Asset Writedown | - | -1.73M | -1.91M | - | - | ||
Other Unusual Items | - | - | - | - | - | ||
EBT, Incl. Unusual Items | -5.08M | -13.7M | -14.17M | -3.33M | -5.22M | ||
Income Tax Expense | - | -248K | - | - | - | ||
Earnings From Continuing Operations | -5.08M | -13.45M | -14.17M | -3.33M | -5.22M | ||
Net Income to Company | -5.08M | -13.45M | -14.17M | -3.33M | -5.22M | ||
Net Income - (IS) | -5.08M | -13.45M | -14.17M | -3.33M | -5.22M | ||
Net Income to Common Incl Extra Items | -5.08M | -13.45M | -14.17M | -3.33M | -5.22M | ||
Net Income to Common Excl. Extra Items | -5.08M | -13.45M | -14.17M | -3.33M | -5.22M | ||
Per Share Items | |||||||
Net EPS - Basic | -0.2 | -0.33 | -0.29 | -0.05 | -0.07 | ||
Basic EPS - Continuing Operations | -0.2 | -0.33 | -0.29 | -0.05 | -0.07 | ||
Basic Weighted Average Shares Outstanding | 25.76M | 40.55M | 49.67M | 67.43M | 78.73M | ||
Net EPS - Diluted | -0.2 | -0.33 | -0.29 | -0.05 | -0.07 | ||
Diluted EPS - Continuing Operations | -0.2 | -0.33 | -0.29 | -0.05 | -0.07 | ||
Diluted Weighted Average Shares Outstanding | 25.76M | 40.55M | 49.67M | 67.43M | 78.73M | ||
Normalized Basic EPS | -0.12 | -0.11 | -0.07 | -0.03 | -0.04 | ||
Normalized Diluted EPS | -0.12 | -0.11 | -0.07 | -0.03 | -0.04 | ||
Supplemental Items | |||||||
EBITDA | - | -6.8M | -5.36M | - | - | ||
EBITA | -5.05M | -7.4M | -5.97M | -3.47M | -5.26M | ||
EBIT | -5.05M | -7.4M | -5.97M | -3.47M | -5.26M | ||
Total Revenues (As Reported) | - | 113K | 89.27K | 456K | 432K | ||
Effective Tax Rate - (Ratio) | - | 1.81 | - | - | - | ||
Total Deferred Taxes | - | -248K | - | - | - | ||
Normalized Net Income | -3.18M | -4.62M | -3.66M | -2.08M | -3.26M | ||
Supplemental Operating Expense Items | |||||||
Advertising Expense | - | 1.18M | 503K | 60.54K | 263K | ||
Selling and Marketing Expenses | - | 1.18M | 503K | 60.54K | 263K | ||
Research And Development Expense From Footnotes | - | - | 610K | - | - | ||
Stock-Based Comp., SG&A Exp. (Total) | - | 609K | 1.12M | 879K | 671K | ||
Stock-Based Comp., Other (Total) | 2.53M | 1.25M | 1.62M | 596K | 820K | ||
Total Stock-Based Compensation | 2.53M | 1.86M | 2.74M | 1.47M | 1.49M |
Select your edition
All financial news and data tailored to specific country editions
